S&P 500   3,849.62
DOW   30,937.04
QQQ   328.59
S&P 500   3,849.62
DOW   30,937.04
QQQ   328.59
S&P 500   3,849.62
DOW   30,937.04
QQQ   328.59
S&P 500   3,849.62
DOW   30,937.04
QQQ   328.59
Log in
NASDAQ:OMCL

Omnicell Stock Forecast, Price & News

$126.23
-1.07 (-0.84 %)
(As of 01/26/2021 12:00 AM ET)
Add
Compare
Today's Range
$124.67
Now: $126.23
$128.41
50-Day Range
$109.88
MA: $118.72
$127.30
52-Week Range
$54.24
Now: $126.23
$128.41
Volume226,328 shs
Average Volume417,421 shs
Market Capitalization$5.34 billion
P/E Ratio145.09
Dividend YieldN/A
Beta1.04
Omnicell, Inc., together with its subsidiaries, provides medication management automation solutions and adherence tools for healthcare systems and pharmacies worldwide. The company offers central pharmacy automation solutions, including automated storage and retrieval systems, such as XR2 Automated Central Pharmacy System, a building block of autonomous pharmacy vision; IV compounding robots and workflow management systems; inventory management software; and controlled substance management systems. It also provides point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; Omnicell Interface Software that offers interface and integration between its medication-use products or supply products, and a healthcare facility's in-house information management systems; and robotic dispensing systems used in hospitals and retail pharmacies for handling the stocking and retrieval of boxed medications. In addition, the company provides single dose automation solutions to fill and label for incoming prescriptions; medication blister card packaging and packaging supplies to enhance medication adherence in non-acute care settings; automated systems to help pharmacies in filling its multimed adherence packaging based on individual patient medication orders; and semi-automated filling equipment for the long-term care institutional pharmacy. Further, it offers Omnicell Patient Engagement, a web-based nexus of solutions; and patient communication tools, such as interactive voice response, outbound communications, and mobile app. The company was formerly known as Omnicell Technologies, Inc. and changed its name to Omnicell, Inc. in 2001. Omnicell, Inc. was founded in 1992 and is headquartered in Mountain View, California.
Omnicell logo

MarketRank

Overall MarketRank

1.53 out of 5 stars

Medical Sector

174th out of 1,925 stocks

Electronic Computers Industry

3rd out of 13 stocks

Analyst Opinion: 1.3Community Rank: 2.8Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 1.9 5 -4 -3 -2 -1 -

Industry, Sector and Symbol

Industry Electronic computers
Sub-IndustryHealth Care Technology
SectorMedical
Current SymbolNASDAQ:OMCL
CUSIP68213N10
Phone650-251-6100
Employees2,700
Year FoundedN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$897.03 million
Cash Flow$4.09 per share
Book Value$20.16 per share

Profitability

Net Income$61.34 million

Miscellaneous

Market Cap$5.34 billion
Next Earnings Date2/1/2021 (Confirmed)
OptionableOptionable
$126.23
-1.07 (-0.84 %)
(As of 01/26/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive OMCL News and Ratings via Email

Sign-up to receive the latest news and ratings for OMCL and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Omnicell (NASDAQ:OMCL) Frequently Asked Questions

How has Omnicell's stock been impacted by Coronavirus (COVID-19)?

Omnicell's stock was trading at $77.41 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, OMCL shares have increased by 63.1% and is now trading at $126.23.
View which stocks have been most impacted by COVID-19
.

Is Omnicell a buy right now?

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Omnicell in the last twelve months. There are currently 3 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Omnicell stock.
View analyst ratings for Omnicell
or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than Omnicell?

Wall Street analysts have given Omnicell a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Omnicell wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

What is Randall A. Lipps' approval rating as Omnicell's CEO?

150 employees have rated Omnicell CEO Randall A. Lipps on Glassdoor.com. Randall A. Lipps has an approval rating of 68% among Omnicell's employees.

When is Omnicell's next earnings date?

Omnicell is scheduled to release its next quarterly earnings announcement on Monday, February 1st 2021.
View our earnings forecast for Omnicell
.

How can I listen to Omnicell's earnings call?

Omnicell will be holding an earnings conference call on Monday, February 1st at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

How were Omnicell's earnings last quarter?

Omnicell, Inc. (NASDAQ:OMCL) posted its quarterly earnings data on Tuesday, October, 27th. The company reported $0.60 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.31 by $0.29. The firm had revenue of $213.70 million for the quarter, compared to analyst estimates of $208.71 million. Omnicell had a trailing twelve-month return on equity of 7.96% and a net margin of 4.25%.
View Omnicell's earnings history
.

What guidance has Omnicell issued on next quarter's earnings?

Omnicell issued an update on its FY21 earnings guidance on Wednesday, January, 13th. The company provided earnings per share (EPS) guidance of $3.38-3.58 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $3.10. The company issued revenue guidance of $1.09-1.11 billion, compared to the consensus revenue estimate of $1.03 billion.

What price target have analysts set for OMCL?

8 Wall Street analysts have issued twelve-month target prices for Omnicell's shares. Their forecasts range from $84.00 to $142.00. On average, they expect Omnicell's stock price to reach $105.29 in the next year. This suggests that the stock has a possible downside of 16.6%.
View analysts' price targets for Omnicell
or view Wall Street analyst' top-rated stocks.

Are investors shorting Omnicell?

Omnicell saw a drop in short interest in the month of December. As of December 31st, there was short interest totaling 1,960,000 shares, a drop of 27.4% from the December 15th total of 2,700,000 shares. Based on an average trading volume of 534,200 shares, the short-interest ratio is presently 3.7 days.
View Omnicell's Short Interest
.

Who are some of Omnicell's key competitors?

What other stocks do shareholders of Omnicell own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Omnicell investors own include AT&T (T), AbbVie (ABBV), Johnson & Johnson (JNJ), Gilead Sciences (GILD), Adobe (ADBE), Micron Technology (MU), NVIDIA (NVDA), Applied Materials (AMAT), Alibaba Group (BABA) and Intel (INTC).

Who are Omnicell's key executives?

Omnicell's management team includes the following people:
  • Mr. Randall A. Lipps, Founder, Exec. Chairman, Pres & CEO (Age 64, Pay $2.28M)
  • Mr. Peter J. Kuipers, Exec. VP & CFO (Age 49, Pay $1.1M)
  • Mr. Daniel S. Johnston, Exec. VP, Chief Legal & Admin. Officer and Corp. Sec. (Age 57, Pay $859.1k)
  • Mr. Nhat H. Ngo, Exec. VP of Marketing, Strategy & Bus. Devel. (Age 48, Pay $946.09k)
  • Mr. Scott Peter Seidelmann, Exec. VP & Chief Commercial Officer (Age 45, Pay $1.05M)
  • Mr. Joseph Brian Spears, Sr. VP, Chief Accounting Officer & Corp. Controller (Age 61)
  • Mr. Giri Chodavarapu, Sr. VP & Chief Information Officer
  • Ms. Kathleen Nemeth, VP of Investor Relations
  • Ms. Susan Moriconi, Sr. VP & Chief HR Officer
  • Mr. Jorge R. Taborga, Exec. VP of Engineering & Integration Management Officer (Age 62)

What is Omnicell's stock symbol?

Omnicell trades on the NASDAQ under the ticker symbol "OMCL."

Who are Omnicell's major shareholders?

Omnicell's stock is owned by many different institutional and retail investors. Top institutional shareholders include Conestoga Capital Advisors LLC (3.82%), Paradigm Capital Management Inc. NY (0.76%), Peregrine Capital Management LLC (0.57%), Scout Investments Inc. (0.56%), Tributary Capital Management LLC (0.56%) and Summit Creek Advisors LLC (0.43%). Company insiders that own Omnicell stock include Dan S Johnston, Gary S Petersmeyer, Joanne B Bauer, Jorge R Taborga, Joseph Brian Spears, Nhat H Ngo, Peter J Kuipers, Randall A Lipps, Robin Gene Seim and Scott Peter Seidelmann.
View institutional ownership trends for Omnicell
.

Which institutional investors are selling Omnicell stock?

OMCL stock was sold by a variety of institutional investors in the last quarter, including Tributary Capital Management LLC, Strs Ohio, Peregrine Capital Management LLC, State of Alaska Department of Revenue, Paradigm Capital Management Inc. NY, Janney Capital Management LLC, Janney Montgomery Scott LLC, and DNB Asset Management AS. Company insiders that have sold Omnicell company stock in the last year include Joanne B Bauer, Peter J Kuipers, Randall A Lipps, Robin Gene Seim, and Scott Peter Seidelmann.
View insider buying and selling activity for Omnicell
or view top insider-selling stocks.

Which institutional investors are buying Omnicell stock?

OMCL stock was acquired by a variety of institutional investors in the last quarter, including Congress Asset Management Co. MA, Scout Investments Inc., Summit Creek Advisors LLC, Conestoga Capital Advisors LLC, Exchange Traded Concepts LLC, 6 Meridian, Great Diamond Partners LLC, and Raymond James Trust N.A..
View insider buying and selling activity for Omnicell
or or view top insider-buying stocks.

How do I buy shares of Omnicell?

Shares of OMCL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Omnicell's stock price today?

One share of OMCL stock can currently be purchased for approximately $126.23.

How big of a company is Omnicell?

Omnicell has a market capitalization of $5.34 billion and generates $897.03 million in revenue each year. The company earns $61.34 million in net income (profit) each year or $2.19 on an earnings per share basis. Omnicell employs 2,700 workers across the globe.

What is Omnicell's official website?

The official website for Omnicell is www.omnicell.com.

How can I contact Omnicell?

Omnicell's mailing address is 590 EAST MIDDLEFIELD ROAD, MOUNTAIN VIEW CA, 94043. The company can be reached via phone at 650-251-6100 or via email at [email protected]

This page was last updated on 1/27/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.